07/01/2024 TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
06/11/2024 TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
05/14/2024 TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update